The reiteration of a Buy rating by a reputable analyst, along with the maintenance of a high price target, typically instills confidence in investors and can lead to a positive short term impact on the stock price. The specific mention of Rhythm Pharmaceuticals and the reaffirmation of the $50 price target suggest a strong conviction in the company's potential.